Acne research has lacked a genuinely novel oral mechanism for decades, which makes the FDA’s August 13, 2026 clearance of Sagimet Biosciences’ Investigational New Drug application for denifanstat a signal worth examining carefully. The agency issued a “Study May Proceed” letter for a Phase 3 trial of the fatty acid synthase (FASN) inhibitor in moderate to severe acne, opening the door to a U.S. pivotal program built on a mechanism that targets sebaceous lipid synthesis rather than bacterial load or systemic retinoid pathways.
The Phase 2 data underpinning this IND clearance are worth revisiting. At Week 12, the 50 mg dose of denifanstat produced a median 61.3% reduction in total lesion counts versus 34.2% for placebo, a separation that held across all tested doses at p less than 0.05. That magnitude of effect in a notoriously noisy indication gave Sagimet the statistical footing to design a Phase 3 program, and the FDA’s green light confirms the agency found the rationale and protocol acceptable. Context matters here: the existing standard of care for severe acne leans heavily on isotretinoin, a drug with a teratogenicity profile serious enough to require the FDA-mandated iPLEDGE Risk Evaluation and Mitigation Strategy. A once-daily oral with a differentiated safety profile, if it holds in Phase 3, addresses a real clinical gap.
Sagimet is not operating in a vacuum on this mechanism. Ascletis, which co-develops denifanstat under a licensing arrangement, presented Phase 3 results for denifanstat in acne at EADV 2025, reporting that the drug met all primary, key secondary, and secondary endpoints in a China trial. A Chinese NDA was accepted in December 2025. That international dataset carries meaningful weight in conversations with U.S. investigators and, eventually, FDA reviewers evaluating the pivotal package.
The single number to watch as this U.S. Phase 3 advances is the Investigator Global Assessment success rate at Week 12. IGA response, not lesion count reduction, is the FDA’s primary benchmark for acne approval, and how cleanly denifanstat clears that threshold in a U.S. population will determine whether this IND clearance translates into an actual NDA submission.
Source link: https://www.sec.gov/Archives/edgar/data/1400118/000119312526347854/d150919d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
